Aproxi 80 mg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Aprepitant |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Prevention of postoperative nausea and vomiting (PONV)
- Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Pharmacology
Aprepitant is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors. It prevents nausea and vomiting by blocking substance P from binding to the NK1 receptors.
Dosage
- Recommended oral dosage of Aprepitant for prevention of postoperative nausea and vomiting: 40 mg within 3 hours prior to induction of anesthesia
- Highly Emetogenic Cancer Chemotherapy:
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg 30 minutes before the start of chemotherapy
- Day 2: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 3: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 4: Dexamethasone 8 mg orally
- Moderately Emetogenic Cancer Chemotherapy:
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg tablet 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later
- Day 2: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
- Day 3: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
Administration
Aprepitant may be taken with or without food. No dosage adjustment is necessary for elderly patients.
Interaction
Aprepitant is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4 and CYP2C9. Precautions should be taken while coadministering Aprepitant with drugs that use CYP3A4 or CYP2C9. Hormonal contraceptive efficacy may be reduced upon coadministration with Aprepitant.
Contraindications
Aprepitant is contraindicated in patients hypersensitive to any component of the product. It should not be used concurrently with Pimozide, Terfenadine, Astemizole, or Cisapride.
Side Effects
- Constipation
- Hypotension
- Pruritus
- Pyrexia
Pregnancy & Lactation
Pregnancy Category B. Use during pregnancy only if clearly needed. Not known whether excreted in human milk. Decision should be made whether to discontinue nursing or the drug based on patient’s importance.
Use in Special Populations
- No dosage adjustment necessary for patients with renal impairment or for patients with end-stage renal disease (ESRD) undergoing hemodialysis
- No dosage adjustment necessary for patients with mild to moderate hepatic impairment. No clinical data available for patients with severe hepatic impairment
Overdose Effects
No specific information available on the treatment of overdosage with Aprepitant. Drowsiness and headache can be seen due to overdose. General supportive treatment and monitoring should be provided. Aprepitant cannot be removed by hemodialysis.
Therapeutic Class
Anti-emetic drugs
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.